What This Protocol Is
A Named Methodology, Not a Marketing Badge
Most research peptide suppliers list products based on market demand. Sequence Labs maintains a formal internal review process — the Catalog Integrity Protocol — that evaluates every compound across four criteria before it is added to the catalog, and re-evaluates it quarterly as the regulatory environment evolves. This process is overseen by Sabrina Runbeck, PA-C, a licensed physician assistant with DEA registration.
The Four-Step Review Framework
How Every Compound Is Evaluated
Step One
Regulatory Status Review
Before any compound enters the catalog, its current regulatory status is verified: Is it on the FDA 503A bulks list? Has it received any warning letters, import alerts, or scheduling actions? Is it classified as a controlled substance or analog? Only compounds with a clear research-use legal pathway proceed.
Step Two
Third-Party Analytical Verification
Every compound in the catalog must have an independently issued Certificate of Analysis (COA) from a licensed third-party analytical laboratory. Sequence Labs partners with accredited labs for HPLC (purity) and mass spectrometry (identity) verification. Purity threshold: ≥98%. COAs are published in the COA Library and linked at the product level.
Step Three
Copy & Claims Review
All product descriptions, compound authority pages, and marketing copy are reviewed against current FDA enforcement precedent — specifically the Gram Peptides warning letter (March 31, 2026) — to ensure no prohibited claims appear anywhere on the site. Prohibited language includes: injection/administration framing, body effect claims, treatment language, or human use framing. All copy must use mechanism-only, research-context language.
Step Four
Ongoing Monitoring & Removal Trigger
Once a compound is in the catalog, it is actively monitored via automated regulatory tracking. Trigger conditions for removal review: FDA warning letter naming the compound, DEA scheduling action, 503A list removal, or FTC enforcement action related to supply or claims. If a removal trigger is identified, the compound is flagged for immediate PA-C review within 48 hours.
Reviewing Practitioner
Catalog Integrity Reviewer
Sabrina Runbeck, PA-C
Physician Assistant-Certified · DEA-Registered · Catalog Integrity Reviewer
Sabrina Runbeck is a licensed Physician Assistant-Certified with an active DEA registration. She reviews the Sequence Labs catalog for regulatory compliance, claim accuracy, and scientific integrity. Her review does not constitute prescribing, clinical advice, or endorsement of any compound for human use. All compounds are offered for research purposes only.
Scope of review: Reviewed by a licensed PA-C & DEA-registered practitioner for catalog integrity — not for clinical use endorsement. This review covers regulatory compliance, claims accuracy, and research-use documentation standards. It does not constitute medical advice, a practitioner-patient relationship, or FDA or DEA authorization of any kind.
Protocol Update History
Review & Revision Log
This log documents when the Catalog Integrity Protocol was established, updated, or expanded in response to regulatory developments. For research use only. Not for human use.
| Date | Update | Trigger |
|---|---|---|
| June 2026 | Initial protocol formalized and published | Brand Launch |
| June 2026 | Gram Peptides warning letter incorporated into copy standards | FDA Enforcement Action |
| June 2026 | PCAC July 2026 compounds added to active monitoring list | Advisory Committee Announcement |
Important Clarification
What This Protocol Is Not
This protocol is an internal standard applied by Sequence Labs LLC to its research compound catalog. It is not a clinical review, medical guideline, or regulatory certification. It does not constitute FDA approval, DEA authorization, or any government endorsement. Sabrina Runbeck PA-C reviews catalog integrity — she does not prescribe, recommend, or endorse any compound for human use. All products are sold for research purposes only, consistent with applicable law.